Advanced breast cancer can be improved and resolved through more robust health systems or pathways, as well as social education, that must be developed across the cancer continuum.
Breast cancer, a heterogenous disease, is often defined based on the hormone receptor expression pattern (estrogen/progesterone receptors and HER2). When breast cancer spreads, it develops into advanced breast cancer, a highly incurable disease.
Advanced breast cancer has a high prevalence rate in low- and middle- income countries, but accurate reports of patients are unlikely because national registries are underreported, and histologic diagnosis required for registry confirmation tend to create difficulties.1
The current approach for treatment includes systemic anticancer therapy, which is incredibly important in the treatment of advanced breast cancer. Endocrine therapy (ET) in conjunction with cyclin-dependent kinase 4/6 inhibitors are the first line standard for HR+ and HER2– breast cancer.
Alternatively, in HER2+ disease, anti–HER2-targeted therapy combines with taxane-based chemotherapy throughout 6 or more cycles. If the disease is HR+, it is typically followed by anti–HER2-targeted therapy up until disease progression or combines with anti-HER2+ ET until disease progression. In cases where the disease is HR+, it will combine with the anti-HER2+ ET until disease progression.
Standard of care for germline BRCA mutation and PD-L1 testing in the triple-negative breast cancer setting is only considered when available. Polymerase inhibitors have gained popularity recently, but access is limited in many low- and middle-income countries, as well as several populations within high income countries.
Disparities within health care systems are prevalent throughout society and patients with advanced breast cancer are not exempt from these prejudices. Later stage diagnosis was found to be more common among marginalized communities, socioeconomically deprived areas, and older women.
A retrospective, multi-institutional cohort study, enrolled patients with stage I to IV breast cancer and evaluated them based on neighborhood disadvantages relating to cancer specific survival using individual sociodemographic, comorbidities, risk factors, access to care, and tumor type. Results found women living under the most disadvantaged conditions were less likely to survive compared with patients living in the most advantaged neighborhoods.2
The study supports the argument that access to preventative medicine is not universal, which can further be proven through the lack of routine funding for medications. For example, tamoxifen, a primary treatment option for advanced breast cancer with an overall response rate of 34%, failed to receive proper funding from clinical commissioning groups for postmenopausal women with a high risk of recurrence.1
In 2019, the advanced breast cancer Global Alliance Meeting in Portugal, a representation of 27 countries, identified unmet needs and gaps in advanced breast cancer care. Patient knowledge gaps surrounded diagnosis and management of advanced breast cancer, the role of patients in shared decision making with physicians, coordination of multidisciplinary care endeavors, access to advanced breast cancer clinical trials, and lack of guidance for friends, family, and caregivers in supporting patients living with advanced breast cancer.
An integral component of the management of advanced breast cancer is palliative care, which focuses on quality of life and symptom control. Patients with advanced breast cancer have benefitted extensively from support groups, navigation programs, and psychosocial interventions. Resources and awareness campaigns have educated an average of 1,176,000 people. Continued training on palliative care and advocacy amongst health care professionals has allowed about 2600 of them to gain new knowledge.
Studies show advanced breast cancer patients benefit from emotional support, clear information, and consistent care. However, low- and middle-income countries face hurdles in training specialist nurses due to workforce shortages, low pay, cultural stigmas, and limited educational resources. Breast cancer care itself can be difficult due to lack of knowledge, cultural barriers, and limited resources.
Global data from the National Cancer Database analyzed records of palliative care used over time between 2004 to 2020.3 While significant increases were evident, underserved populations were the least likely to receive palliative care. Non-Hispanic Black, Asian, or Pacific Islander, and Hispanic patients were 13%, 26%, and 35% less likely to have the option for palliative treatment compared with non-Hispanic White patients and those who identified as American Indian, Alaska Native, or another ethnicity.
Specialist nurses with expertise in oncology and palliative care help improve patient satisfaction and overall care. Advanced breast cancer education focuses on disease background, treatment options, supportive care, communication, cultural competency, emotional intelligence, teamwork, leadership, and self-care for nurses.
However, research found there are unmet needs in establishing a comprehensive, accessible advanced breast cancer education and specialized training programs overcoming geographic and linguistic disparities. Currently, there is an international online education program directed for nurses that includes translations from 15 different languages, acting as a potential solution to the inequalities existing within the health care system.
To improve breast cancer outcomes globally, countries need stronger health systems, public education, and research focused on specific populations. Funding and addressing social factors are crucial to ensure equitable access to care throughout the entire cancer journey, keeping the patient at the core.
References
1. Ghose A, Stanway S, Bhawna Sirohi, Mutebi M, Adomah S. Advanced breast cancer care: The current situation and global disparities. Semin Oncol Nurs. 2024;40(1):1-5.doi:10.1016/j.soncn.2023.151551
2. Goel N, Hernandez A, Thompson C, et al. Neighborhood disadvantage and breast cancer–specific survival. JAMA Netw Open. 2023;6(4):e238908. doi:10.1001/jamanetworkopen.2023.8908
3. Racial/ethnic minority patients may be less likely than white patients to receive palliative care during breast cancer treatment. American Association for Cancer Research (AACR). September 29, 2023. Accessed April 30, 2024. https://www.aacr.org/about-the-aacr/newsroom/news-releases/racial-ethnic-minority-patients-may-be-less-likely-than-white-patients-to-receive-palliative-care-during-breast-cancer-treatment/#:~:text=However%2C%20non%2DHispanic%20Black%2C
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Breast cancer costs. | Image Credit: Cozine - stock.adobe.com
Advanced breast cancer can be improved and resolved through more robust health systems or pathways, as well as social education, that must be developed across the cancer continuum.
Breast cancer, a heterogenous disease, is often defined based on the hormone receptor expression pattern (estrogen/progesterone receptors and HER2). When breast cancer spreads, it develops into advanced breast cancer, a highly incurable disease.
Advanced breast cancer has a high prevalence rate in low- and middle- income countries, but accurate reports of patients are unlikely because national registries are underreported, and histologic diagnosis required for registry confirmation tend to create difficulties.1
The current approach for treatment includes systemic anticancer therapy, which is incredibly important in the treatment of advanced breast cancer. Endocrine therapy (ET) in conjunction with cyclin-dependent kinase 4/6 inhibitors are the first line standard for HR+ and HER2– breast cancer.
Alternatively, in HER2+ disease, anti–HER2-targeted therapy combines with taxane-based chemotherapy throughout 6 or more cycles. If the disease is HR+, it is typically followed by anti–HER2-targeted therapy up until disease progression or combines with anti-HER2+ ET until disease progression. In cases where the disease is HR+, it will combine with the anti-HER2+ ET until disease progression.
Standard of care for germline BRCA mutation and PD-L1 testing in the triple-negative breast cancer setting is only considered when available. Polymerase inhibitors have gained popularity recently, but access is limited in many low- and middle-income countries, as well as several populations within high income countries.
Disparities within health care systems are prevalent throughout society and patients with advanced breast cancer are not exempt from these prejudices. Later stage diagnosis was found to be more common among marginalized communities, socioeconomically deprived areas, and older women.
A retrospective, multi-institutional cohort study, enrolled patients with stage I to IV breast cancer and evaluated them based on neighborhood disadvantages relating to cancer specific survival using individual sociodemographic, comorbidities, risk factors, access to care, and tumor type. Results found women living under the most disadvantaged conditions were less likely to survive compared with patients living in the most advantaged neighborhoods.2
The study supports the argument that access to preventative medicine is not universal, which can further be proven through the lack of routine funding for medications. For example, tamoxifen, a primary treatment option for advanced breast cancer with an overall response rate of 34%, failed to receive proper funding from clinical commissioning groups for postmenopausal women with a high risk of recurrence.1
In 2019, the advanced breast cancer Global Alliance Meeting in Portugal, a representation of 27 countries, identified unmet needs and gaps in advanced breast cancer care. Patient knowledge gaps surrounded diagnosis and management of advanced breast cancer, the role of patients in shared decision making with physicians, coordination of multidisciplinary care endeavors, access to advanced breast cancer clinical trials, and lack of guidance for friends, family, and caregivers in supporting patients living with advanced breast cancer.
An integral component of the management of advanced breast cancer is palliative care, which focuses on quality of life and symptom control. Patients with advanced breast cancer have benefitted extensively from support groups, navigation programs, and psychosocial interventions. Resources and awareness campaigns have educated an average of 1,176,000 people. Continued training on palliative care and advocacy amongst health care professionals has allowed about 2600 of them to gain new knowledge.
Studies show advanced breast cancer patients benefit from emotional support, clear information, and consistent care. However, low- and middle-income countries face hurdles in training specialist nurses due to workforce shortages, low pay, cultural stigmas, and limited educational resources. Breast cancer care itself can be difficult due to lack of knowledge, cultural barriers, and limited resources.
Global data from the National Cancer Database analyzed records of palliative care used over time between 2004 to 2020.3 While significant increases were evident, underserved populations were the least likely to receive palliative care. Non-Hispanic Black, Asian, or Pacific Islander, and Hispanic patients were 13%, 26%, and 35% less likely to have the option for palliative treatment compared with non-Hispanic White patients and those who identified as American Indian, Alaska Native, or another ethnicity.
Specialist nurses with expertise in oncology and palliative care help improve patient satisfaction and overall care. Advanced breast cancer education focuses on disease background, treatment options, supportive care, communication, cultural competency, emotional intelligence, teamwork, leadership, and self-care for nurses.
However, research found there are unmet needs in establishing a comprehensive, accessible advanced breast cancer education and specialized training programs overcoming geographic and linguistic disparities. Currently, there is an international online education program directed for nurses that includes translations from 15 different languages, acting as a potential solution to the inequalities existing within the health care system.
To improve breast cancer outcomes globally, countries need stronger health systems, public education, and research focused on specific populations. Funding and addressing social factors are crucial to ensure equitable access to care throughout the entire cancer journey, keeping the patient at the core.
References
1. Ghose A, Stanway S, Bhawna Sirohi, Mutebi M, Adomah S. Advanced breast cancer care: The current situation and global disparities. Semin Oncol Nurs. 2024;40(1):1-5.doi:10.1016/j.soncn.2023.151551
2. Goel N, Hernandez A, Thompson C, et al. Neighborhood disadvantage and breast cancer–specific survival. JAMA Netw Open. 2023;6(4):e238908. doi:10.1001/jamanetworkopen.2023.8908
3. Racial/ethnic minority patients may be less likely than white patients to receive palliative care during breast cancer treatment. American Association for Cancer Research (AACR). September 29, 2023. Accessed April 30, 2024. https://www.aacr.org/about-the-aacr/newsroom/news-releases/racial-ethnic-minority-patients-may-be-less-likely-than-white-patients-to-receive-palliative-care-during-breast-cancer-treatment/#:~:text=However%2C%20non%2DHispanic%20Black%2C
Higher Prevalence of Asthma Exacerbations Found in Patients With Insomnia
May 16th 2024Underlying mood and sleep disorders may negatively affect asthma control, researchers find.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
FDA Grants Accelerated Approval for Liso-Cel for R/R Follicular Lymphoma
May 16th 2024FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
Scalp Repair Serum Microneedling: Fewer Treatments, More Hair Regrowth for AGA
May 14th 2024A study found scalp repair serum microneedle combined therapy with medication to improve hair growth outcomes for patients with moderate to severe androgenetic alopecia (AGA) and reduce the number of microneedling sessions necessary.
Read More
Alopecia Areata Risk Associated With Atopy, Allergies
May 13th 2024A genetic study suggests people with allergies and eczema are more likely to develop alopecia areata, an autoimmune disease that causes hair loss. Researchers believe this link may be due to similar immune system responses.
Read More
Higher Prevalence of Asthma Exacerbations Found in Patients With Insomnia
May 16th 2024Underlying mood and sleep disorders may negatively affect asthma control, researchers find.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
FDA Grants Accelerated Approval for Liso-Cel for R/R Follicular Lymphoma
May 16th 2024FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
Scalp Repair Serum Microneedling: Fewer Treatments, More Hair Regrowth for AGA
May 14th 2024A study found scalp repair serum microneedle combined therapy with medication to improve hair growth outcomes for patients with moderate to severe androgenetic alopecia (AGA) and reduce the number of microneedling sessions necessary.
Read More
Alopecia Areata Risk Associated With Atopy, Allergies
May 13th 2024A genetic study suggests people with allergies and eczema are more likely to develop alopecia areata, an autoimmune disease that causes hair loss. Researchers believe this link may be due to similar immune system responses.
Read More